Ubrogepant Shows Positive Results for Acute Treatment of Migraines

Phase 3 subjects achieved pain relief after two hours when compared to a placebo

In the Pipeline - A PPM Brief

Migraine headaches are an extraordinarily common neurological disease, affecting 39 million people in the United States alone.1 More than four million migraine sufferers have chronic daily migraines, or at least 15 migraines per month.1 Yet, the disease is often under-diagnosed, leaving migraine sufferers without effective relief from the pain and related symptoms.

An oral CGRP receptor antagonist in Phase 3 testing by Allergan (Dublin) may soon offer a new treatment option for acute migraine pain. ACHIEVE I, the first of two Phase 3 clinical trials evaluating the efficacy, safety, and tolerability of ubrogepant, included 1,327 adult participants. Subjects either received 50 mg or 100 mg of ubrogepant or placebo to treat a single migraine attack of moderate or severe intensity.2

“There remains a need for new treatments with improved benefit-risk profiles,” said lead investigator Richard B. Lipton, MD, vice chair of neurology and director of the Montefiore Headache Center in a company release. “Results from this ubrogepant phase 3 trial are important in progressing the research and developing therapies to help migraine patients.”

Adverse events of ubrogepant were comparable to placebo, with the most common being nausea, somnolence, and dry mouth, none of which were reported with a frequency of greater than 5%.2 Liver issues were minimal, with instances of high aminotransferase levels in participants being accompanied by alternative explanations, such as illness or medication, none of which were noted by the liver safety adjudication board as having a probable relationship to ubrogepant.2

“We are confident that ubrogepant will be an option for the treatment of migraines in adults,” said Allergan’s Chief Research & Development Office David Nicholson in a company release.

Update 4/30/18: Allergan has announced positive results from their second Phase 3 Trial (ACHIEVE II) on Ubrogepant. Click here to learn more.

Vertical Health Media, LLC does not, by publication of the advertisements contained herein, express endorsement or verify the accuracy and effectiveness of the products and claims contained therein. Vertical Health Media, LLC disclaims any liability for damages resulting from the use of any product advertised herein and suggests that readers fully investigate the products and claims prior to purchasing. The views of the authors are not necessarily those of Vertical Health Media, LLC.

Practical Pain Management is sent without charge 10 times per year to pain management clinicians in the US.

Use of this website is conditional upon your acceptance of our user agreement.